Loading...
•
Mar 31, 2024
Corcept Therapeutics Q1 2024 Earnings Report
Reported a revenue increase of 39% compared to the same period in 2023, with a net income per share of $0.25 (diluted).
Key Takeaways
Corcept Therapeutics announced first quarter financial results with revenue of $146.8 million, a 39% increase over the same period in 2023. The company increased its 2024 revenue guidance to $620 - $650 million.
Revenue of $146.8 million, a 39 percent increase over the same period in 2023
Increased 2024 revenue guidance to $620 – $650 million, from $600 – $630 million
Net income per common share of $0.25 (diluted), compared to $0.14 in first quarter 2023
Cash and investments of $451.0 million as of March 31, 2024
Revenue by Segment
Forward Guidance
The company increased its 2024 revenue guidance to $620 – $650 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...